Drugs / BPI-421286
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05315180 | Aug 2021 → Jul 2023 | metastatic malignant neoplasm | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-421286 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05315180 ↗ |
| Route | Oral | “following administration as an oral Tablet formulation” NCT05315180 ↗ |